MiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.

Rhea-AI Summary

MiniMed (Nasdaq: MMED) has commercially launched the MiniMed Flex™ system in the U.S., its first app-controlled and smallest insulin pump, paired initially with the Simplera Sync™ sensor.

The pump holds 300 units, uses the SmartGuard™ algorithm with Meal Detection™ technology, and real‑world data showed about 80% Time in Range with recommended settings. FDA clearance covers type 1 diabetes from age 7 and insulin‑requiring type 2 adults.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

• First U.S. launch of MiniMed Flex™ app-controlled insulin pump
• Pump about half size of prior MiniMed models, holds 300 units
• SmartGuard™ algorithm with Meal Detection™ and 5‑minute autocorrections
• Real‑world results show around 80% Time in Range with settings
• Extended™ infusion set allows up to seven days of wear
• FDA clearance for type 1 (7+) and insulin‑requiring type 2 adults

Negative

• None.

News Market Reaction – MMED

-3.61%

1 alert

-3.61% News Effect

-$162M Valuation Impact

$4.32B Market Cap

0.0x Rel. Volume

On the day this news was published, MMED declined 3.61%, reflecting a moderate negative market reaction. This price movement removed approximately $162M from the company's valuation, bringing the market cap to $4.32B at that time.

Data tracked by StockTitan Argus on the day of publication.

What This Means

This announcement marks the first commercial U.S. launch of the MiniMed Flex™ system, pairing a comp...

Analysis

This announcement marks the first commercial U.S. launch of the MiniMed Flex™ system, pairing a compact, app-controlled insulin pump holding 300 units with the Simplera Sync™ sensor. It builds on prior FDA clearance and showcases of the platform, reinforcing MiniMed’s strategy around SmartGuard™ automation and extended-wear sets that allow up to 7 days of use. Against the backdrop of strong but unprofitable growth reported in recent filings, investors may track adoption, reimbursement dynamics, and future updates on Flex-related financial performance.

Key Figures

Pump insulin capacity: 300 units Time in Range: 80% Infusion set wear time: 7 days +5 more

8 metrics

Pump insulin capacity 300 units MiniMed Flex™ reservoir size

Time in Range 80% Real-world TIR with recommended settings

Infusion set wear time 7 days MiniMed Extended™ infusion set maximum wear

Injection reduction 96% fewer injections Compared to traditional insulin therapy

Auto-adjust frequency Every 5 minutes SmartGuard™ algorithm insulin delivery adjustments

Minimum age type 1 7 years and older FDA-cleared indication for type 1 diabetes

Adult type 2 indication 18 years and older FDA-cleared indication for insulin-requiring type 2 diabetes

Time in Range users 24 adults Randomized crossover trial size cited in prior MiniMed 780G study

Historical Context

5 past events · Latest: Jun 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 03	Sensor partnership expansion	Positive	+15.9%	Expanded Abbott deal for dual glucose‑ketone sensors for MiniMed systems.
Jun 03	Earnings and outlook	Positive	+15.9%	Strong Q4 and FY 2026 results with FY 2027 growth and margin guidance.
May 27	Conference product showcase	Neutral	-3.4%	Showcase of MiniMed Flex™ and Go™ at ADA Scientific Sessions.
May 26	Investor conference appearance	Neutral	-5.8%	Participation in Goldman Sachs Global Healthcare Conference fireside chat.
May 21	Clinical outcomes update	Positive	+0.8%	Study showing strong glycemic outcomes across sensors with MiniMed 780G.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent product and partnership news often aligned with positive price moves, while conference-related headlines saw weaker or negative reactions.

Recent Company History

Over the last few months, MiniMed has highlighted expanded sensor partnerships, strong fiscal 2026 results, and preparations for key product launches like MiniMed Flex™ and MiniMed Go™. News on Abbott dual glucose‑ketone sensors and robust earnings both preceded +15.93% moves, suggesting investors responded positively to clear growth and pipeline visibility. In contrast, conference participation and showcase announcements on May 26 and May 27 coincided with declines, indicating less enthusiasm for purely promotional events. The current U.S. launch of MiniMed Flex™ follows those earlier clearances and showcases.

Key Terms

insulin pump, infusion set, fda cleared

3 terms

insulin pump medical

"MiniMed's smallest pump, paired with the Simplera Sync™ sensor"

A small wearable medical device that delivers measured doses of insulin automatically or on demand to help people with diabetes regulate their blood sugar, often replacing multiple daily injections. Investors care because these devices combine hardware, software and supplies to create recurring revenue, are subject to regulatory approval and reimbursement decisions, and can change competitive dynamics in a large, growing healthcare market much like a smartphone platform reshapes accessory sales.

infusion set medical

"Compatible with MiniMed's Extended™ infusion set, users can also benefit"

An infusion set is the small medical kit—tube, connector and tiny plastic or soft tube that sits on or under the skin—that delivers drugs or fluids from a pump or IV into a patient’s bloodstream or tissue. For investors it matters because these parts are high-volume, regulated consumables whose reliability, safety and supply affect recurring revenue, product recalls and regulatory risk for companies that make or sell them — like the hose and nozzle for a pump.

fda cleared regulatory

"The MiniMed Flex™ system is FDA cleared for people with type 1 diabetes"

FDA cleared means the U.S. Food and Drug Administration reviewed a medical device and agreed it is similar enough to an already allowed product to be marketed in the United States. Think of it like a new car model using largely the same, proven parts as an earlier model — the regulator gives a green light for sales but does not imply the more extensive testing required for full approval. For investors, clearance signals regulatory access to the U.S. market and typically lowers commercialization risk compared with no clearance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

People with type 1 or insulin-requiring type 2 diabetes in the U.S. can now wear MiniMed's smallest pump, paired with the Simplera Sync™ sensor

NORTHRIDGE, Calif., June 17, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), today announced its first commercial launch of the MiniMed Flex™ system in the United States — its first app-controlled pump and the company's smallest insulin pump yet. The system launches with Simplera Sync™ sensor, a disposable, all-in-one sensor with easy two-step insertion. The launch with the Instinct sensor, made by Abbott, will follow later this summer.*  

For years, people who use insulin pumps have had to think about where and how they wear their device each day. While diabetes technology has advanced, many still had to choose between clinical performance and a pump that works with their lifestyle. Few products have offered both.

Designed to let diabetes take a backseat, the MiniMed Flex™ system gives people the freedom to live on their own terms without sacrificing the clinical performance they depend on. About half the size** of other MiniMed pumps, it's the company's most compact pump while still holding 300 units of insulin. It is engineered to fit into everyday life no matter what a person wants to wear.

"For too long, people managing diabetes have had to choose between effective therapy and the freedom to just live their lives. MiniMed Flex™ changes that," said Que Dallara, chief executive officer of MiniMed. "It's small enough to disappear, smart enough to handle the hard work, and now it's in people's hands. This is the MiniMed we're becoming — faster, and more focused than ever on delivering on our Mission. Better days start now."

The MiniMed Flex™ system is powered by MiniMed's most advanced SmartGuard™ algorithm — the only system with Meal Detection™ technology that detects rapid rises in sensor glucose and delivers a correction dose for occasional missed meal boluses or underestimated carb counts.^§ Working seamlessly in the background, the system continuously adjusts and autocorrects insulin delivery up to every 5 minutes^‡ based on real-time glucose readings from the Simplera Sync™ sensor, helping users spend more time in their target range with less daily effort. Real-world results have demonstrated 80% Time in Range (TIR)¹ with recommended settings — exceeding worldwide TIR recommendations.^◊ Compatible with MiniMed's Extended™ infusion set, users can also benefit from up to seven days of wear and up to 96% fewer injections compared to traditional insulin therapy. ^Δ

"Having worked with people using MiniMed Flex™, I've seen firsthand how app control can simplify everyday diabetes management," said Anders Carlson, MD, executive director, International Diabetes Center, and director, HealthPartners diabetes program; assistant professor, University of Minnesota Medical School. "For many patients, two devices are central to daily life: their automated insulin delivery system and their phone. Bringing those experiences together, while continuing to leverage the trusted MiniMed algorithm, represents a meaningful evolution in how diabetes technology can support people throughout the day."

The MiniMed Flex™ system is FDA cleared for people with type 1 diabetes ages 7 years and older, as well as adults ages 18 years and older with insulin-requiring type 2 diabetes.

Reimbursement support and access programs are available through MiniMed's customer support team. For more information and to order MiniMed Flex™ visit minimed.com/en-us/products/minimed-flex-system.

About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.

Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

References

1. Arrieta A, et al. Diabetes Obes Metab. 2022;10.1111/dom.14714 .

*MiniMed Flex™ system with Instinct sensor is investigational. Not cleared by the FDA for any use and not commercially available in the U.S.

**Compared to MiniMed™ 780G pump

§Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating.

‡Refers to SmartGuard^TM feature. Individual results may vary.

◊Due to inherent real-world study limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.

ΔAssumes 4 injections per day for 30 days and one infusion set change every seven days.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/minimeds-smallest-app-controlled-insulin-pump-is-now-available-in-the-us-302802777.html

SOURCE MiniMed

FAQ

What is the MiniMed Flex™ system launched by MiniMed (NASDAQ: MMED) on June 17, 2026?

The MiniMed Flex™ system is MiniMed’s first app-controlled, smallest insulin pump now available in the U.S. According to MiniMed, it holds 300 units of insulin, works with continuous glucose sensors, and aims to fit more discreetly into daily life.

How is the MiniMed Flex™ insulin pump different from other MiniMed pumps (MMED)?

MiniMed Flex™ is about half the size of other MiniMed pumps while still holding 300 units. According to MiniMed, it integrates app control, SmartGuard™ automation, and compatibility with Simplera Sync™ and later the Instinct sensor to support more flexible wear options.

Who is eligible to use the MiniMed Flex™ system from MiniMed (MMED)?

The MiniMed Flex™ system is FDA cleared for people with type 1 diabetes aged 7 and older. According to MiniMed, it is also cleared for adults 18 and older with insulin‑requiring type 2 diabetes, expanding access beyond traditional pump users.

How does the SmartGuard™ algorithm in the MiniMed Flex™ system help diabetes management?

SmartGuard™ uses sensor glucose data to adjust insulin every five minutes and includes Meal Detection™ technology. According to MiniMed, it can deliver correction doses for occasional missed or underestimated meals, aiming to increase time in target glucose range with less daily effort.

What Time in Range results have been reported for the MiniMed Flex™ system (MMED)?

Real‑world use of MiniMed Flex™ with recommended settings has shown about 80% Time in Range. According to MiniMed, this performance exceeds worldwide Time in Range recommendations and reflects the system’s automated insulin adjustments based on continuous sensor readings.

Which sensors work with the MiniMed Flex™ insulin pump and when is Instinct available?

At launch, MiniMed Flex™ pairs with the Simplera Sync™ disposable, all‑in‑one sensor featuring two‑step insertion. According to MiniMed, a launch with the Instinct sensor, produced by Abbott, is planned to follow later in the summer.

What infusion set and wear-time options does the MiniMed Flex™ system support?

MiniMed Flex™ is compatible with the MiniMed Extended™ infusion set, designed for up to seven days of wear. According to MiniMed, this can mean up to 96% fewer injections compared with traditional insulin therapy regimens for many users.